TP53 and myelodysplastic syndrome: [3-8] Previous studies have consistently shown that TP53 mutations are associated with higher-risk MDS, therapy-related disease, complex cytogenetics (including chromosome 5, 7 and 17 abnormalities), and poor overall survival.